SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificate

25 Jan 2024 Evaluate

Pursuant to Regulation 39 and other application regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulations’), GlaxoSmithKline Pharmaceuticals has informed that Registrar and Transfer Agent of Company - KFin Technologies has received request for issue of duplicate Share Certificates from Shareholder, details of which are enclosed. The company will issue the Letter of Confirmation only after the necessary formalities are carried out by the Shareholder.

The above information is a part of company’s filings submitted to BSE.


Glaxosmithkline Phar Share Price

2393.25 32.95 (1.40%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×